Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
17
SYRS Quote, Financials, Valuation and Earnings
Last price:
$0.0000
Seasonality move
:
8.82%
Day range:
$0.0005 - $0.0008
52-week range:
$0.0001 - $0.3100
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.05x
P/B ratio:
9.66x
Volume:
4.4K
Avg. volume:
23.1K
1-year change:
-99.8%
Market cap:
$13.4K
Revenue:
$9.9M
EPS (TTM):
-$3.07
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SYRS
Syros Pharmaceuticals, Inc.
|
-- | -$0.76 | -6.74% | -68.02% | -- |
|
AFFY
Affymax, Inc.
|
-- | -- | -- | -- | -- |
|
CNBX
CNBX Pharmaceuticals, Inc.
|
-- | -- | -- | -- | -- |
|
CTBO
Cantabio Pharmaceuticals, Inc.
|
-- | -- | -- | -- | -- |
|
SCPS
Scopus Biopharma, Inc.
|
-- | -- | -- | -- | -- |
|
TRVN
Trevena, Inc.
|
-- | -$2.50 | -100% | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SYRS
Syros Pharmaceuticals, Inc.
|
$0.0005 | -- | $13.4K | -- | $0.00 | 0% | 0.05x |
|
AFFY
Affymax, Inc.
|
$0.0011 | -- | $41.2K | -- | $0.00 | 0% | 0.98x |
|
CNBX
CNBX Pharmaceuticals, Inc.
|
$0.0005 | -- | $249.3K | -- | $0.00 | 0% | 0.03x |
|
CTBO
Cantabio Pharmaceuticals, Inc.
|
$1.01 | -- | $22.7K | -- | $0.00 | 0% | -- |
|
SCPS
Scopus Biopharma, Inc.
|
$0.0005 | -- | $21K | -- | $0.00 | 0% | -- |
|
TRVN
Trevena, Inc.
|
$0.0120 | -- | $10.4K | -- | $0.00 | 0% | 0.02x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SYRS
Syros Pharmaceuticals, Inc.
|
-- | 4.330 | -- | -- |
|
AFFY
Affymax, Inc.
|
-- | 0.114 | -- | -- |
|
CNBX
CNBX Pharmaceuticals, Inc.
|
-111.93% | -2.979 | 1073.02% | 0.01x |
|
CTBO
Cantabio Pharmaceuticals, Inc.
|
-- | 0.000 | -- | -- |
|
SCPS
Scopus Biopharma, Inc.
|
-- | -1.071 | -- | -- |
|
TRVN
Trevena, Inc.
|
343.69% | -1.477 | 1028.29% | 2.21x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SYRS
Syros Pharmaceuticals, Inc.
|
-- | -$26.2M | -- | -- | -- | -$20.7M |
|
AFFY
Affymax, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CNBX
CNBX Pharmaceuticals, Inc.
|
-- | -$40.4K | -- | -- | -507.98% | -$52K |
|
CTBO
Cantabio Pharmaceuticals, Inc.
|
-- | -- | -- | -- | -- | -- |
|
SCPS
Scopus Biopharma, Inc.
|
-- | -- | -- | -- | -- | -- |
|
TRVN
Trevena, Inc.
|
$169K | -$5.6M | -178.87% | -17098.81% | -1734.28% | -$4.5M |
Syros Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns SYRS or AFFY?
Affymax, Inc. has a net margin of -- compared to Syros Pharmaceuticals, Inc.'s net margin of --. Syros Pharmaceuticals, Inc.'s return on equity of -- beat Affymax, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SYRSSyros Pharmaceuticals, Inc.-- -$0.16 -- AFFYAffymax, Inc.-- -- -- -
What do Analysts Say About SYRS or AFFY?
Syros Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 199900%. On the other hand Affymax, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Syros Pharmaceuticals, Inc. has higher upside potential than Affymax, Inc., analysts believe Syros Pharmaceuticals, Inc. is more attractive than Affymax, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRSSyros Pharmaceuticals, Inc.0 3 0 AFFYAffymax, Inc.0 0 0 -
Is SYRS or AFFY More Risky?
Syros Pharmaceuticals, Inc. has a beta of 1.113, which suggesting that the stock is 11.326% more volatile than S&P 500. In comparison Affymax, Inc. has a beta of 7.774, suggesting its more volatile than the S&P 500 by 677.424%.
-
Which is a Better Dividend Stock SYRS or AFFY?
Syros Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Affymax, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syros Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Affymax, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRS or AFFY?
Syros Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Affymax, Inc. quarterly revenues of --. Syros Pharmaceuticals, Inc.'s net income of -$6.4M is higher than Affymax, Inc.'s net income of --. Notably, Syros Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Affymax, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syros Pharmaceuticals, Inc. is 0.05x versus 0.98x for Affymax, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRSSyros Pharmaceuticals, Inc.0.05x -- -- -$6.4M AFFYAffymax, Inc.0.98x -- -- --
-
Which has Higher Returns SYRS or CNBX?
CNBX Pharmaceuticals, Inc. has a net margin of -- compared to Syros Pharmaceuticals, Inc.'s net margin of -800.89%. Syros Pharmaceuticals, Inc.'s return on equity of -- beat CNBX Pharmaceuticals, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SYRSSyros Pharmaceuticals, Inc.-- -$0.16 -- CNBXCNBX Pharmaceuticals, Inc.84.69% -- -$1.2M -
What do Analysts Say About SYRS or CNBX?
Syros Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 199900%. On the other hand CNBX Pharmaceuticals, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Syros Pharmaceuticals, Inc. has higher upside potential than CNBX Pharmaceuticals, Inc., analysts believe Syros Pharmaceuticals, Inc. is more attractive than CNBX Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRSSyros Pharmaceuticals, Inc.0 3 0 CNBXCNBX Pharmaceuticals, Inc.0 0 0 -
Is SYRS or CNBX More Risky?
Syros Pharmaceuticals, Inc. has a beta of 1.113, which suggesting that the stock is 11.326% more volatile than S&P 500. In comparison CNBX Pharmaceuticals, Inc. has a beta of -0.358, suggesting its less volatile than the S&P 500 by 135.795%.
-
Which is a Better Dividend Stock SYRS or CNBX?
Syros Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CNBX Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syros Pharmaceuticals, Inc. pays -- of its earnings as a dividend. CNBX Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRS or CNBX?
Syros Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than CNBX Pharmaceuticals, Inc. quarterly revenues of --. Syros Pharmaceuticals, Inc.'s net income of -$6.4M is lower than CNBX Pharmaceuticals, Inc.'s net income of -$59.7K. Notably, Syros Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while CNBX Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syros Pharmaceuticals, Inc. is 0.05x versus 0.03x for CNBX Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRSSyros Pharmaceuticals, Inc.0.05x -- -- -$6.4M CNBXCNBX Pharmaceuticals, Inc.0.03x -- -- -$59.7K
-
Which has Higher Returns SYRS or CTBO?
Cantabio Pharmaceuticals, Inc. has a net margin of -- compared to Syros Pharmaceuticals, Inc.'s net margin of --. Syros Pharmaceuticals, Inc.'s return on equity of -- beat Cantabio Pharmaceuticals, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SYRSSyros Pharmaceuticals, Inc.-- -$0.16 -- CTBOCantabio Pharmaceuticals, Inc.-- -- -- -
What do Analysts Say About SYRS or CTBO?
Syros Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 199900%. On the other hand Cantabio Pharmaceuticals, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Syros Pharmaceuticals, Inc. has higher upside potential than Cantabio Pharmaceuticals, Inc., analysts believe Syros Pharmaceuticals, Inc. is more attractive than Cantabio Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRSSyros Pharmaceuticals, Inc.0 3 0 CTBOCantabio Pharmaceuticals, Inc.0 0 0 -
Is SYRS or CTBO More Risky?
Syros Pharmaceuticals, Inc. has a beta of 1.113, which suggesting that the stock is 11.326% more volatile than S&P 500. In comparison Cantabio Pharmaceuticals, Inc. has a beta of -0.149, suggesting its less volatile than the S&P 500 by 114.935%.
-
Which is a Better Dividend Stock SYRS or CTBO?
Syros Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cantabio Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syros Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Cantabio Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRS or CTBO?
Syros Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Cantabio Pharmaceuticals, Inc. quarterly revenues of --. Syros Pharmaceuticals, Inc.'s net income of -$6.4M is higher than Cantabio Pharmaceuticals, Inc.'s net income of --. Notably, Syros Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Cantabio Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syros Pharmaceuticals, Inc. is 0.05x versus -- for Cantabio Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRSSyros Pharmaceuticals, Inc.0.05x -- -- -$6.4M CTBOCantabio Pharmaceuticals, Inc.-- -- -- --
-
Which has Higher Returns SYRS or SCPS?
Scopus Biopharma, Inc. has a net margin of -- compared to Syros Pharmaceuticals, Inc.'s net margin of --. Syros Pharmaceuticals, Inc.'s return on equity of -- beat Scopus Biopharma, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SYRSSyros Pharmaceuticals, Inc.-- -$0.16 -- SCPSScopus Biopharma, Inc.-- -- -- -
What do Analysts Say About SYRS or SCPS?
Syros Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 199900%. On the other hand Scopus Biopharma, Inc. has an analysts' consensus of -- which suggests that it could grow by 2399900%. Given that Scopus Biopharma, Inc. has higher upside potential than Syros Pharmaceuticals, Inc., analysts believe Scopus Biopharma, Inc. is more attractive than Syros Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRSSyros Pharmaceuticals, Inc.0 3 0 SCPSScopus Biopharma, Inc.0 0 0 -
Is SYRS or SCPS More Risky?
Syros Pharmaceuticals, Inc. has a beta of 1.113, which suggesting that the stock is 11.326% more volatile than S&P 500. In comparison Scopus Biopharma, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SYRS or SCPS?
Syros Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Scopus Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syros Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Scopus Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRS or SCPS?
Syros Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Scopus Biopharma, Inc. quarterly revenues of --. Syros Pharmaceuticals, Inc.'s net income of -$6.4M is higher than Scopus Biopharma, Inc.'s net income of --. Notably, Syros Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Scopus Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syros Pharmaceuticals, Inc. is 0.05x versus -- for Scopus Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRSSyros Pharmaceuticals, Inc.0.05x -- -- -$6.4M SCPSScopus Biopharma, Inc.-- -- -- --
-
Which has Higher Returns SYRS or TRVN?
Trevena, Inc. has a net margin of -- compared to Syros Pharmaceuticals, Inc.'s net margin of -1745.23%. Syros Pharmaceuticals, Inc.'s return on equity of -- beat Trevena, Inc.'s return on equity of -17098.81%.
Company Gross Margin Earnings Per Share Invested Capital SYRSSyros Pharmaceuticals, Inc.-- -$0.16 -- TRVNTrevena, Inc.59.72% -$5.79 $9.6M -
What do Analysts Say About SYRS or TRVN?
Syros Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 199900%. On the other hand Trevena, Inc. has an analysts' consensus of -- which suggests that it could grow by 41566.67%. Given that Syros Pharmaceuticals, Inc. has higher upside potential than Trevena, Inc., analysts believe Syros Pharmaceuticals, Inc. is more attractive than Trevena, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRSSyros Pharmaceuticals, Inc.0 3 0 TRVNTrevena, Inc.0 0 0 -
Is SYRS or TRVN More Risky?
Syros Pharmaceuticals, Inc. has a beta of 1.113, which suggesting that the stock is 11.326% more volatile than S&P 500. In comparison Trevena, Inc. has a beta of 0.602, suggesting its less volatile than the S&P 500 by 39.809%.
-
Which is a Better Dividend Stock SYRS or TRVN?
Syros Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trevena, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syros Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Trevena, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRS or TRVN?
Syros Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Trevena, Inc. quarterly revenues of $283K. Syros Pharmaceuticals, Inc.'s net income of -$6.4M is lower than Trevena, Inc.'s net income of -$4.9M. Notably, Syros Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Trevena, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syros Pharmaceuticals, Inc. is 0.05x versus 0.02x for Trevena, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRSSyros Pharmaceuticals, Inc.0.05x -- -- -$6.4M TRVNTrevena, Inc.0.02x -- $283K -$4.9M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 123.09% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 1.11% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 1.33% over the past day.
